000289187 001__ 289187
000289187 005__ 20241029140424.0
000289187 0247_ $$2doi$$a10.3390/pathogens13030184
000289187 0247_ $$2pmid$$apmid:38535528
000289187 037__ $$aDKFZ-2024-00622
000289187 041__ $$aEnglish
000289187 082__ $$a610
000289187 1001_ $$0P:(DE-He78)34bd069ab74ead9ac824c1e0896ecbf0$$aAngelova, Assia Ludmilova$$b0$$eFirst author$$udkfz
000289187 245__ $$aThe Complex Role of Infectious Agents in Human Cutaneous T-Cell Lymphoma Pathogenesis: From Candidate Etiological Factors to Potential Therapeutics.
000289187 260__ $$aBasel$$bMDPI$$c2024
000289187 3367_ $$2DRIVER$$aarticle
000289187 3367_ $$2DataCite$$aOutput Types/Journal article
000289187 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1711630465_21797$$xReview Article
000289187 3367_ $$2BibTeX$$aARTICLE
000289187 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000289187 3367_ $$00$$2EndNote$$aJournal Article
000289187 500__ $$a#EA:F230#LA:F230# / NEU  #EA:D490#LA:D490#
000289187 520__ $$aCutaneous T-cell lymphoma (CTCL) is a devastating, potentially fatal T-lymphocyte malignancy affecting the skin. Despite all efforts, the etiology of this disease remains unknown. Infectious agents have long been suspected as factors or co-factors in CTCL pathogenesis. This review deals with the panel of bacterial and viral pathogens that have been investigated so far in an attempt to establish a potential link between infection/carriage and CTCL development. A special focus is given to a recently discovered human protoparvovirus, namely the cutavirus (CutaV), which has emerged as a plausible CTCL etiological agent. Available evidence in support of this hypothesis as well as alternative interpretations and uncertainties raised by some conflicting data are discussed. The complexity and multifacetedness of the Parvoviridae family of viruses are illustrated by presenting another protoparvovirus, the rat H-1 parvovirus (H-1PV). H-1PV belongs to the same genus as the CutaV but carries considerable potential for therapeutic applications in cutaneous lymphoma.
000289187 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000289187 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000289187 650_7 $$2Other$$aParvoviridae
000289187 650_7 $$2Other$$acutaneous T-cell lymphoma
000289187 650_7 $$2Other$$acutavirus
000289187 650_7 $$2Other$$ainfectious etiology
000289187 650_7 $$2Other$$aoncolytic H-1 parvovirus
000289187 7001_ $$0P:(DE-He78)2d7958ea507b0b738619074b38ec6d54$$aRommelaere, Jean$$b1$$udkfz
000289187 7001_ $$0P:(DE-He78)833f90e2abdd29594ad5c4f08600f191$$aUngerechts, Guy$$b2$$eLast author$$udkfz
000289187 773__ $$0PERI:(DE-600)2695572-6$$a10.3390/pathogens13030184$$gVol. 13, no. 3, p. 184 -$$n3$$p184$$tPathogens$$v13$$x2076-0817$$y2024
000289187 8564_ $$uhttps://inrepo02.dkfz.de/record/289187/files/pathogens-13-00184.pdf
000289187 8564_ $$uhttps://inrepo02.dkfz.de/record/289187/files/pathogens-13-00184.pdf?subformat=pdfa$$xpdfa
000289187 8564_ $$uhttps://inrepo02.dkfz.de/record/289187/files/jcm-13-02194-v2.pdf
000289187 8564_ $$uhttps://inrepo02.dkfz.de/record/289187/files/jcm-13-02194-v2.pdf?subformat=pdfa$$xpdfa
000289187 909CO $$ooai:inrepo02.dkfz.de:289187$$pVDB
000289187 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)34bd069ab74ead9ac824c1e0896ecbf0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000289187 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2d7958ea507b0b738619074b38ec6d54$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000289187 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)833f90e2abdd29594ad5c4f08600f191$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000289187 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000289187 9141_ $$y2024
000289187 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPATHOGENS : 2022$$d2023-10-26
000289187 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000289187 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000289187 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000289187 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:01:22Z
000289187 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:01:22Z
000289187 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:01:22Z
000289187 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-04-12T15:01:22Z
000289187 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000289187 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000289187 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-26
000289187 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000289187 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-26
000289187 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-26
000289187 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-26
000289187 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-26
000289187 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-26
000289187 9202_ $$0I:(DE-He78)F230-20160331$$kF230$$lKKE Virotherapie$$x0
000289187 9202_ $$0I:(DE-He78)D490-20160331$$kD490$$lKKE Virotherapie$$x1
000289187 9201_ $$0I:(DE-He78)F230-20160331$$kF230$$lKKE Virotherapie$$x0
000289187 9201_ $$0I:(DE-He78)D490-20160331$$kD490$$lKKE Virotherapie$$x1
000289187 9200_ $$0I:(DE-He78)F230-20160331$$kF230$$lKKE Virotherapie$$x0
000289187 9200_ $$0I:(DE-He78)D490-20160331$$kD490$$lKKE Virotherapie$$x1
000289187 980__ $$ajournal
000289187 980__ $$aVDB
000289187 980__ $$aI:(DE-He78)F230-20160331
000289187 980__ $$aI:(DE-He78)D490-20160331
000289187 980__ $$aUNRESTRICTED